Trials / Completed
CompletedNCT04492618
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Aaron R. Mangold · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica |
Timeline
- Start date
- 2020-09-29
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
- First posted
- 2020-07-30
- Last updated
- 2023-02-08
- Results posted
- 2023-02-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04492618. Inclusion in this directory is not an endorsement.